BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Galecto, Inc. announced that it has completed a review of its business, including the status of its programs, resources, and capabilities.

HilleVax, Inc. announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST.

Medpace Holdings, Inc. announced that it will report its third quarter 2023 financial results after the market close on Monday, October 23, 2023.

SK Biopharmaceuticals and Proteovant Therapeutics, today announced they will present data on the discovery and characterization of a selective IKZF2 molecular glue degrader with best-in-class potential, and on MOPED™, a novel platform for the discovery of molecular glues, at the 20th Annual Discovery on Target Conference being held in Boston, September 25-28, 2023.

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that Telitacicept(RC18) for injection obtained positive results in a Phase III clinical study in the treatment of patients with rheumatoid arthritis(RA) in China.

Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced positive clinical data with onvansertib monotherapy and combination therapy in our ongoing trials in metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC), as well as plans for a mPDAC first-line investigator-initiated trial (IIT) of the combination of onvansertib plus standard-of-care (SoC).

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference in New York City on Tuesday, October 3, at 1:00 p.m. ET.

Morphic Holdings Inc. announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence.

GENFIT announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis diagnostic technology NIS4® by the FNIH’s NIMBLE project in the scientific journal, Nature Medicine.